Publication | Open Access

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Chemotherapy Versus ChemotherapyEsophageal CancerGastrointestinal OncologyMedicineCheckmate 649GastroenterologySurgeryOesophageal AdenocarcinomaOncologyRadiation Oncology